COMP <GO>
ADPT vs MRK // ENTERPRISE SCALE & MARKET CAP
Adaptive Biotechnologies Corporation (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ADPT 3
— MRK 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $26.64 (-5.43%) • MKT CAP: $4.50B
market-cap
$4.50B
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADPT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADPT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 74.80% | -0.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.50% | 20.70% | -33.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.09% | 3.42% | -4.51 | MRK | /fcf-yield <GO> |
| Operating Margin | -20.60% | 34.30% | -54.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 28.10% | -49.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 54.80% | 1.30% | +53.50 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.32 | 5.19 | +1.13 | ADPT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.3 | 56.9 | -5.61 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.92 | +0.09 | ADPT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.0x | 18.4x | +7.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $4.50B | $361.02B | -$356.53B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADPT REV | MRK REV | ADPT GROSS % | MRK GROSS % | ADPT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $277.0M | $65.01B | 74.2% | 74.8% | -$48.9M | $12.36B |
| FY 2024 | $179.0M | $64.17B | 59.7% | 76.3% | -$98.9M | $18.10B |
| FY 2023 | $170.3M | $60.12B | 44.0% | 44.0% | -$164.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADPT // BETA 1.01
MRK // BETA 0.92